Welcome to our dedicated page for TELO GENOMICS news (Ticker: $TDSGF), a resource for investors and traders seeking the latest updates and insights on TELO GENOMICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TELO GENOMICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TELO GENOMICS's position in the market.
Rhea-AI Summary
Telo Genomics Corp. (TDSGF) receives accreditation from the College of American Pathologists (CAP) for its laboratory in Toronto, Canada, enhancing quality and patient outcomes. The accreditation recognizes the company's commitment to excellence in its telomere technology platform, paving the way for commercialization and partnerships in the diagnostic and prognostic sectors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.71%
Tags
-
Rhea-AI Summary
Telo Genomics Corp. initiates patient recruitment for its MRD clinical trial, expanding to three additional hospitals in Montreal to accelerate the study. The company aims to reduce patient recruitment time by up to 50% and enhance trial reliability. MRD testing is a promising tool in oncology, with the global market expected to reach USD 4.1 billion by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.23%
Tags
-
Rhea-AI Summary
Telo Genomics Corp. receives first patient sample for MRD study in multiple myeloma patients post-treatment, aiming to develop prognostic tests using TeloView technology. The MRD global testing market is expected to reach USD 4.1 billion by 2032.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
Rhea-AI Summary
Telo Genomics Corp. has engaged Trusted Health Advisors to refine and accelerate its go-to-market and partnership deployment plan for biomarker services in cancer research. The engagement will be led by industry veterans and will focus on facilitating partnerships and collaborations with various organizations. The Company's clinical studies have led to the prioritization of this engagement as part of its commercialization strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) will present TeloViewSMM at the 2023 ASH meeting, marking a significant milestone as the assay becomes commercially available. TeloViewSMM is a non-invasive liquid biopsy that utilizes 3D telomere analysis to quantify genomic instability and transformation risk, offering potential benefits for patients diagnosed with Smoldering Multiple Myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
-
Rhea-AI Summary
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) announces the initiation of the Physician Experience Program - SMART, an observational study for cancer treating physicians in the US to gain experience ordering and utilizing the TeloViewSMM assay. The assay uses 3-dimensional telomere analysis to quantify genomic instability and transformation risk, helping in the selection of management strategies for patients diagnosed with Smoldering Multiple Myeloma. The launch aims to improve patient management and introduce the assay to a wider physician user base.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
News
Rhea-AI Summary
Telo Genomics Corp. has successfully completed its certification application with the College of American Pathologists (CAP) Accreditation Office, marking a crucial step towards the full commercial availability of its TeloView diagnostic tests. The company expects to complete the CAP audit within the first quarter of 2024 and anticipates that this accreditation will facilitate wider adoption of its tests in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Telo Genomics Corp. announces that the American Society of Hematology (ASH) has accepted the results of their TeloView-SMM technical repeatability validation study for presentation at their annual meeting in December. The study, led by Dr. Hans Knecht, will be presented on December 10, 2023. ASH regulations require the study results to be under embargo until presented. The ASH Annual Meeting and Exposition will take place from December 9-12, 2023, in San Diego, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.48%
Tags
-
Rhea-AI Summary
Telo Genomics Corp. has received its Certificate of Accreditation of ISO 15189, allowing it to offer its Laboratory Developed Tests (LDT) internationally. This accreditation is a significant achievement for the company's platform of novel cancer assays. Telo Genomics will initially focus on testing for Smoldering Multiple Myeloma (SMM), a precursor to Multiple Myeloma (MM).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Telo Genomics Corp. announces the launch of its TeloViewSMM diagnostic platform to clinicians in the United States. The platform combines molecular biology and AI to analyze telomeres and predict the progression of multiple cancers, starting with Smoldering Multiple Myeloma (SMM). The test is available for physicians to order under the SMART protocol.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
TELO GENOMICS CORP
OTC:TDSGF
TDSGF Rankings
TDSGF Stock Data
10.68M
65.96M
5.59%
2.87%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
United States of America
Toronto